Anavex Life Sciences Corp (AVXL)

[Doc328]

Most of their communications raise more questions than they answer. Hard to spin "Additionally, the comprehensive data from the blarcamesine Alzheimer’s disease program represents a solid foundation for the subsequent strategy of our Phase III and IV development plan." positively but its ambiguous enough that it could be neutral. Missling will need to clarify this precisely later this week --- for now I will stick with 3-4% possibility of approval without an additional trial.